A differentiated effector T cell repertoire defines a functionally high-risk group of smoldering myeloma patients - Top-Institutions - MDSpire

A differentiated effector T cell repertoire defines a functionally high-risk group of smoldering myeloma patients

  • By

  • Ross S. Firestone

  • Anish K. Simhal

  • Theresia Akhlaghi

  • Jung Hun Oh

  • Devin McAvoy

  • Kylee H. Maclachlan

  • Juan-Jose Garces

  • Sham Mailankody

  • Hani Hassoun

  • Urvi A. Shah

  • Neha Korde

  • Carlyn R. Tan

  • Sridevi Rajeeve

  • Hamza Hashmi

  • Alexander M. Lesokhin

  • Kinga Hosszu

  • Francesco Maura

  • Joseph O. Deasy

  • Saad Z. Usmani

  • Malin Hultcrantz

  • May 1, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology
    • Oncology

  • #2

    Emory University Winship Cancer Institute
    Emory University Winship Cancer Institute

    Atlanta, GA

    Key Differentiators

    • Hematology
    • Oncology

  • #3

    Winship Cancer Institute of Emory University
    Winship Cancer Institute of Emory University

    Atlanta, GA

    Key Differentiators

    • Hematology
    • Oncology

  • #4

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Oncology

  • #5

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology

Original Source(s)

A differentiated effector T cell repertoire defines a functionally high-risk group of smoldering myeloma patients

  • by Ross S. Firestone, Anish K. Simhal, Theresia Akhlaghi, Jung Hun Oh, Devin McAvoy, Kylee H. Maclachlan, Juan-Jose Garces, Sham Mailankody, Hani Hassoun, Urvi A. Shah, Neha Korde, Carlyn R. Tan, Sridevi Rajeeve, Hamza Hashmi, Alexander M. Lesokhin, Kinga Hosszu, Francesco Maura, Joseph O. Deasy, Saad Z. Usmani, Malin Hultcrantz

  • May 1, 2026

Related Content

Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy

Recurrent IDH-mutant astrocytoma WHO grade 4 diagnosed during pregnancy: case report with literature review